Therapeutic Asset Ratings

184 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cetuximab Triple Negative Breast Cancer	Pfizer	P3	B (60)
Eribulin Triple Negative Breast Cancer	Hu Hai	P3	B (60)
Everolimus Triple Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P3	B (60)
Gdc-0068 Triple Negative Breast Cancer	MedSIR	P3	B (60)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Triple Negative Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (60)
Irinotecan Triple Negative Breast Cancer	Fudan University	P3	B (60)
Sacituzumab Tirumotecan Triple Negative Breast Cancer	Yale University	P3	B (60)
TRASTUZUMAB Triple Negative Breast Cancer	Fudan University	P3	B (60)
LENVATINIB Triple Negative Breast Cancer	Fudan University	P2	B (60)
Enzalutamide Triple Negative Breast Cancer	Nuvation Bio Inc.	P2	B (59)
Zimberelimab Triple Negative Breast Cancer	MedSIR	P2	B (59)
Nivolumab Triple Negative Breast Cancer	Yale University	P2	B (58)
Palbociclib Triple Negative Breast Cancer	Avenzo Therapeutics, Inc.	P2	B (58)
Trilaciclib Triple Negative Breast Cancer	Wake Forest University Health Sciences	P3	B (57)
FULVESTRANT Triple Negative Breast Cancer	Pfizer	P2	B (57)
Tinengotinib Triple Negative Breast Cancer	TransThera Sciences (Nanjing), Inc.	P1/2	B (57)
Huaier Granule Triple Negative Breast Cancer	Fudan University	P4	B (56)
Viscum Album Triple Negative Breast Cancer	Ilsan Cha hospital	P4	B (56)
Avelumab Triple Negative Breast Cancer	Ocellaris Pharma, Inc.	P3	B (56)
Serplulimab Triple Negative Breast Cancer	Shanghai Henlius Biotech	P3	B (56)
Datopotamab Deruxtecan Triple Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P2	B (56)
ETOPOSIDE Triple Negative Breast Cancer	Xijing Hospital	P2	B (56)
Niraparib Triple Negative Breast Cancer	Zhejiang Cancer Hospital	P2	B (56)
rc48-adc Triple Negative Breast Cancer	Seagen, a wholly owned subsidiary of Pfizer	P2	B (56)
Talzenna Triple Negative Breast Cancer	University of Malaya	P2	B (56)

Showing 26 to 50 of 184 assets

PreviousPage 2 of 8Next